Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 102

    1.

    Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes.

    Kilpatrick ES, Rigby AS, Atkin SL.

    Diabetes Care. 2009 Oct;32(10):1901-3. Epub 2009 Jun 23.PMID: 19549736 [PubMed - in process]Related articles

    3.

    A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial.

    Kilpatrick ES, Rigby AS, Atkin SL.

    Diabetes Care. 2008 Nov;31(11):2198-202. Epub 2008 Jul 23.PMID: 18650371 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    The effect of glucose variability on the risk of microvascular complications in type 1 diabetes.

    Kilpatrick ES, Rigby AS, Atkin SL.

    Diabetes Care. 2006 Jul;29(7):1486-90.PMID: 16801566 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study.

    Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.

    JAMA. 2003 Oct 22;290(16):2159-67.PMID: 14570951 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Effect of intensive glycemic control and diabetes complications on lower urinary tract symptoms in men with type 1 diabetes: Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study.

    Van Den Eeden SK, Sarma AV, Rutledge BN, Cleary PA, Kusek JW, Nyberg LM, McVary KT, Wessells H; Diabetes Control and Complications Trial/Epidemiology of Diabetes Research Group.

    Diabetes Care. 2009 Apr;32(4):664-70. Epub 2009 Jan 26.PMID: 19171725 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT).

    White NH, Cleary PA, Dahms W, Goldstein D, Malone J, Tamborlane WV; Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group.

    J Pediatr. 2001 Dec;139(6):804-12.PMID: 11743505 [PubMed - indexed for MEDLINE]Related articles

    8.

    Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial.

    White NH, Sun W, Cleary PA, Danis RP, Davis MD, Hainsworth DP, Hubbard LD, Lachin JM, Nathan DM.

    Arch Ophthalmol. 2008 Dec;126(12):1707-15.PMID: 19064853 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study.

    Cleary PA, Orchard TJ, Genuth S, Wong ND, Detrano R, Backlund JY, Zinman B, Jacobson A, Sun W, Lachin JM, Nathan DM; DCCT/EDIC Research Group.

    Diabetes. 2006 Dec;55(12):3556-65.PMID: 17130504 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC).

    Pop-Busui R, Low PA, Waberski BH, Martin CL, Albers JW, Feldman EL, Sommer C, Cleary PA, Lachin JM, Herman WH; DCCT/EDIC Research Group.

    Circulation. 2009 Jun 9;119(22):2886-93. Epub 2009 May 26.PMID: 19470886 [PubMed - in process]Related articles

    14.

    Multiple variants in vascular endothelial growth factor (VEGFA) are risk factors for time to severe retinopathy in type 1 diabetes: the DCCT/EDIC genetics study.

    Al-Kateb H, Mirea L, Xie X, Sun L, Liu M, Chen H, Bull SB, Boright AP, Paterson AD; DCCT/EDIC Research Group.

    Diabetes. 2007 Aug;56(8):2161-8. Epub 2007 May 18.PMID: 17513698 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    The Diabetes Control and Complications Trial: the gift that keeps giving.

    Kilpatrick ES, Rigby AS, Atkin SL.

    Nat Rev Endocrinol. 2009 Oct;5(10):537-45.PMID: 19763126 [PubMed - in process]Related articles

    19.

    A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes.

    Wadén J, Forsblom C, Thorn LM, Gordin D, Saraheimo M, Groop PH; Finnish Diabetic Nephropathy Study Group.

    Diabetes. 2009 Nov;58(11):2649-55. Epub 2009 Aug 3.PMID: 19651819 [PubMed - in process]Related articles

    20.

    Comparison of fingerstick hemoglobin A1c levels assayed by DCA 2000 with the DCCT/EDIC central laboratory assay: results of a Diabetes Research in Children Network (DirecNet) Study.

    Tamborlane WV, Kollman C, Steffes MW, Ruedy KJ, Dongyuan X, Beck RW, Chase P, Fox LA, Wilson DM, Tsalikian E; Diabetes Research in Children Network (DirecNet) Study Group.

    Pediatr Diabetes. 2005 Mar;6(1):13-6.PMID: 15787896 [PubMed - indexed for MEDLINE]Related articles